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Abstract
Introduction A feature of rheumatoid arthritis (RA) is an
imbalance between proinflammatory and anti-inflammatory
cytokines. Several recent studies have implicated polymorphism
in the IL-4 signalling pathway in the development of erosive RA.
The aim of the present study was to investigate the role of
polymorphism in the IL-4, IL-4Rα and IL-13 genes in RA,
including an examination of epistasis.
Methods A total of 965 Caucasian patients with RA (cases) and
988 healthy control individuals (controls) were genotyped for
five variants in the IL-4/IL-13 gene cluster (5q31.1) and two
functional variants IL-4Rα (16p12.1). Individual genotype and
haplotype frequencies were compared between cases and
controls. The odd ratios were calculated with asymptotic 95%
confidence intervals, and P  values less than 0.05 were
considered statistically significant. The potential association
with radiological joint damage was also examined. Potential
gene interactions were assessed using both stratified analysis
and the linkage disequilibrium-based statistic.
Results Genotype, allele and haplotype frequencies were
equally distributed between RA cases and controls. Similarly, no
association was detected between these variants and modified
Larsen scores. Furthermore, no evidence of epistasis was
detected between IL-4 or IL-13 genotypes and IL-4Rα.
Conclusion These results indicate that common variants of the
IL-4/IL-13 pathway do not significantly contribute to RA
susceptibility and radiological severity.
Introduction
Rheumatoid arthritis (RA) is the commonest autoimmune dis-
ease with a prevalence of 1% worldwide. Two loci, DRB1 and
PTPN22, have been reproducibly implicated in the genetic
background of RA. Advances in high-throughput genotyping
and bioinformatics have allowed genome-wide assocation
studies to be performed. The Wellcome Trust Case Control
Consortium reported associations of nine novel variants with
RA [1]. A subsequent UK case-control study confirmed asso-
ciation of one of the markers, rs6920220, with an intergenic
region between the oligodendrocyte lineage transcription fac-
tor 3 and tumour necrosis factor (TNF)-α-induced protein 3
genes at 6q23.3 with RA [2]. However, of the other eight
markers, only rs743777 in the IL2RB gene exhibited weak evi-
dence of association. The association of the region encom-
passing OLIG3-TNFAIP3 was independently identified in a
US study that combined both a case-control and genome-
wide association study [3]. Another genome wide study involv-
ing 1,622 RA patients and 1,850 healthy control individuals
revealed significant association within a 100 kilobase region
on chromosome 9 encompassing the TRAF1-C5 genes [4].
The signal transducer and activator of transcription (STAT)4
gene was also recently implicated in susceptibility to RA [5].
A central feature of RA is a relative imbalance in proinflamma-
tory and anti-inflammatory cytokines, with high levels of TNF,
IL-1 and IL-6, but much lower levels of IL-4 and IL-13 [6]. The
recognition that dysregulated production of cytokines was
important in the pathogenesis of RA leads directly to the suc-
cessful use of TNF and IL-1 inhibitors.
The genes for the anti-inflammatory cytokines IL-4 and IL-13
are located in a gene cluster at 5q31.1. Their effects are medi-
CI = confidence interval; HWE = Hardy-Weinberg equilibrium; IL = interleukin; LD = linkage disequilibrium; OR = odds ratio; RA = rheumatoid arthri-
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ated by a heterodimeric receptor composed of the IL-4Rα
chain (16p12.1) and either the common γ chain or the IL-13Rα
subunit [5]. IL-4, also known as B-cell-stimulating factor, was
the first B-cell growth factor discovered. It mainly promotes
proliferation of T cells and induces antibody production by B
cells. IL-13 is a T-cell-specific cytokine that has a 30% protein
homology with IL-4, and it stimulates proliferation and differen-
tiation of B cells and induces IgE and IgM production.
The role played by these genes in RA susceptibility and sever-
ity is not clearly established. An IL-4 variable number tandem
repeat has been associated with both RA susceptibility and
lesser radiological damage [7]. A promoter single nucleotide
polymorphism (SNP) in IL-4 -590 (rs2243250), which is asso-
ciated with enhanced IL-4 activity [8], has also been associ-
ated with more severe RA [9]. However, this polymorphism
was not associated with RA susceptibility in a large case-con-
trol study [10]. The IL-4 -590 T allele is associated with three-
fold higher promoter activity as well as IgE production in Jurkat
cells [11]. More recently, a study suggested that a nonsynon-
ymous SNP located in the IL-4 binding site of the IL-4R gene
was associated with rapidly erosive RA during the first 2 years
of disease, and that this was independent of other risk markers
such as HLA-DRB1 and autoantibodies [12].
In this study we examined the potential role of IL-4, IL-13 and
IL-4R SNPs in RA susceptibility and severity. In addition, we
also investigated epistasis between the IL-4 or IL-13 and their
common receptor IL-4Rα.
Materials and methods
Study populations
A total of 965 white Caucasian individuals with RA (cases)
and 988 healthy unrelated individuals (controls) participated in
this study and were described previously [13]. The South
Sheffield Research Ethics Committee approved this study and
informed consent was obtained from all participants. RA was
diagnosed according to the American College of Rheumatol-
ogy diagnostic criteria. Radiographs of hands and feet were
scored blind at study entry by a single musculoskeletal radiol-
ogist using a modification to Larsen's score [14]. Larsen's
method measures the amount of destruction by assessing 32
joints, including 16 areas in both hands (eight joints in each
hand), eight areas in both wrists (four joints in each wrist) and
eight joints in both feet (four areas in each foot) [15].
SNP selection
In addition to the functional SNPs I50V and Q551R in the IL-
4R gene, SNPs in the IL-4 and IL-13 genes were selected
using a haplotype-tagging approach. Haplotype-tagging
SNPs were selected using the genotyping data from the CEU
(Centre d'Etude du Polymorphisme Human from Utah) study
group (30 US trios recruited in 1980 from US residents with
Northern and Western European ancestry), available from the
International Hapmap project [16], using the Tagger algorithm
implemented by Paul de Bakker (available through Haploview
software) [5]. Selection was undertaken using the pairwise-
tagging option with an r2 of 0.8 and minor allele frequency
greater than 10%. We selected three IL-4 SNPs that allowed
us to define the haplotypes described in the Hapmap project.
Tagging of the promoter IL-4 -590 variant was achieved using
rs2243267 (r2 = 0.94). For IL-13 one SNP was selected cap-
turing five additional SNPs. We also genotyped the promoter
polymorphism -1112 (rs1800925), which has been shown to
alter binding of the STAT transcription factor and levels of IL-
13 in T cells [7].
SNP genotyping
Blood samples were collected in EDTA-anticoagulated tubes
and DNA was extracted using standard methods. All SNPs
genotyped using Taqman technology (Applied Biosciences,
ABI, Warrington, UK). Multiple positive and negative controls
were included in all genotyping plates to ensure genotyping
data and 10% of the samples were repeated to eliminate gen-
otyping errors. Multiple positive and negative controls were
included in all genotyping plates to ensure quality of genotyp-
ing data. Genotypes were also confirmed by sequencing.
Thermal cycling in 384-well plates was performed on PTC-
225 DNA engine Tetrad (MJ Research, San Francisco, CA,
USA), and genotypes were determined using an ABI Prism
7900 HT (PE Biosystems, Foster City, CA, USA).
Statistical analysis
Hardy-Weinberg equilibrium (HWE) of each SNP was
assessed in cases and controls separately using a χ2 test with
one degree of freedom. A threshold P < 0.05 was regarded to
indicate deviation from HWE. Allele and genotype frequencies
were calculated and associations with susceptibility to RA
were tested by calculating odds ratios (ORs) with asymptotic
95% confidence intervals (CIs), and P values less than 0.05
were considered statstically significant. Haplotype association
analysis was performed using SNPStats, a web-based tool
that allows the estimation of haplotypes frequencies using the
expectation-maximization (EM) algorithm.
Gene-gene interactions between different variants were
tested using two different approaches. We stratified the study
subjects according to the genotype of one gene and per-
formed the analysis of the other gene on different strata using
the Mantel-Haenszel test. Deviation from independence of
penetrance in two unlinked loci (referred to as the linkage dis-
equilibrium [LD]-based statistic) was also used to detect
gene-gene interactions; this method is derived from the
assumption that interaction between two unlinked loci creates
LD in a disease population, the level of which depends on the
extent of the interaction. A total of seven tests for main effects
and 10 for gene-gene interactions (17 tests in total) were per-
formed. All statistical analyses were carried out using STATA
statistical software (Release 9.1; STATA Corporation, College
Station, TX, USA).Available online http://arthritis-research.com/content/10/4/R80
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We then examined the potential influence of each variant in
disease severity. Dichotomized variables were created for
both rheumatoid factor and anti-cyclic citrullinated peptide lev-
els, as previously described. Modified Larsen score differ-
ences were tested for associations with each candidate gene
polymorphism using the nonparametric Kruskal-Wallis test.
Results
Single marker association analysis of IL-4, IL-13 and IL-
4R SNPs with RA susceptibility
We successfully genotyped SNPs in IL-4, IL-13 and IL-4R
genes, tagging one block for IL-4 and one block for IL-13. All
polymorphisms under study were in HWE in both cases and
controls, separately. Tagging of the promoter IL-4 -590 variant
was achieved using rs2243267. No significant associations
were detected (Table 1) apart from a marginal association of
the IL-4R AG (I50/V50) genotype (50.7% versus 46.6%; OR
= 1.3, 95% CI = 1.0 to 1.6; P = 0.03). No other association
was detected in the single SNP analysis.
LD and haplotype analysis
To assess the extent of LD across the IL-4 and IL-13 genes,
we calculated D' values. The pair-wise D' values in the IL-4
gene were nearly 1 (Table 2) among all SNPs, indicating very
strong LD. Interestingly, the IL-13 SNPs were not in strong LD
with each other or with the IL-4 polymorphisms (D' < 0.5).
As the two IL-13 SNPs are in different LD blocks than the
three IL-4 SNPs, the haplotypes of the markers of the two
genes were analyzed separately. Haplotype analysis of IL-13
predicted four haplotypes, all of which had a frequency above
1%. Compared with the most common haplotype CG, which
is automatically selected as the reference haplotype, none of
the haplotypes exhibited a significantly different distribution
between cases and controls. For IL-4 a total of eight haplo-
types were predicted, only three of which had a frequency
above 1%. Again, no significant difference was detected
between RA cases and healthy controls (Table 3).
Single marker analysis with RA severity
We then examined the potential influence of these markers on
Table 1
Genotype frequencies and RA susceptibility
Gene SNP Genotypes RA (n [%]) Controls (n [%]) OR (95% CI) P value
IL-13 rs1800925 TT 26 (2.9) 26 (2.8) 1.0 (0.6–1.9) 0.9
CT 271 (29.9) 276 (29.6) 1.0 (0.8–1.3) 0.9
CC 608 (67.2) 631 (67.6) 1.0
rs1295686 TT 26 (3.0) 31 (3.3) 0.9 (0.5–1.6) 0.7
CT 251 (29.3) 283 (30.4) 0.9 (0.8–1.2) 0.6
CC 580 (67.7) 617 (66.3) 1.0
IL-4 rs2227284 AA 56 (6.1) 47 (4.9) 1.2 (0.8–1.9) 0.3
AC 316 (34.6) 349 (36.7) 0.9 (0.8–1.1) 0.4
CC 541 (59.3) 554 (58.3) 1.0
rs2243263 CC 8 (0.9) 6 (0.6) 1.4 (0.4–4.8) 0.6a
GC 146 (16.4) 166 (17.9) 0.9 (0.7–1.2) 0.4
GG 738 (82.7) 753 (81.4) 1.0
rs2243267 CC 18 (2.0) 17 (1.8) 1.1 (0.5–2.3) 0.8a
CG 218 (24.0) 205 (22.2) 1.1 (0.9–1.4) 0.4
GG 672 (74.0) 702 (76.0) 1.0
IL-4R rs1805010 GG 198 (21.8) 200 (21.3) 1.2 (0.9–1.5) 0.2
AG 460 (50.7) 438 (46.6) 1.3 (1.0–1.6) 0.03
AA 250 (27.5) 301 (32.1) 1.0
rs1801275 AA 38 (4.2) 41 (4.3) 1.0 (0.6–1.6) 1.0
AG 316 (34.6) 302 (32.0) 1.1 (0.9–1.4) 0.2
GG 558 (61.2) 601 (63.7) 1.0
aFisher's exact test. CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 10 No 4    Marinou et al.
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disease severity, as defined by Modified Larsen scores and
production of autoantibodies. No association was detected
between the SNPs under study and markers of disease sever-
ity (Tables 4 and 5).
Gene-gene interactions between IL-4, IL-13 and IL-4R 
SNPs
The presence of epistatic interactions was initially examined by
stratification analysis (Mantel-Haenszel test). Suggestive evi-
dence of interactions was found when IL-4R Q551R was
stratified by IL-13 -1112. The OR comparing individuals with
the AA/AG genotypes at the IL-4R Q551R locus in partici-
pants who were TT at the IL-13 -1112 locus was higher than
in those having either CC or CT genotypes (OR = 5.9 versus
1.0 in those who had the CC genotype and 1.3 in those having
the CT genotype; P = 0.01 by Mantel-Haenszel test). How-
ever, these results are based on very small numbers and, after
correction, the interaction is not statistically significant. No
other interaction was detected.
Discussion
In this study we conducted a haplotype-tagging approach to
investigate the role played by the IL-4/IL-13 pathway in RA in
a large case-control cohort. This approach allows us to exam-
ine the contribution of these genes with RA in a more robust
manner than has previously been reported. Studies have
reported the association of IL-4 and IL-4R with both RA sus-
ceptibility and severity [7,17,18], whereas the contribution of
IL-13 variation has not previously been examined in RA. In our
cohort single SNP analysis as well as haplotype analysis pro-
vided evidence of no association between RA development
and variation in the IL-4/IL-13 pathway. Both genotype and
allele frequencies were similar between cases and controls.
Haplotype CGAGC yielded only a suggestive evidence for
association, with a P value of 0.05. This haplotype contains the
rare A allele of rs2227284 and the rare C allele of rs2243267,
which are in high LD (D' = 0.98). Although none of this SNPs
are known to be functional, the rs2243263 is in complete LD
with the IL-4 -590 variant, which has been associated with dif-
ferential promoter activity [5].
The IL-4R I50V variant has been associated with increased
radiological damage during the first 2 years of disease [7], but
we did not observe such an association. This conflicting find-
ing could be due to differences in study design; our study is
composed of a cross-sectional cohort with minimum disease
duration of 3 years, whereas Prots and colleagues [7] con-
ducted a prospective study with a follow up of 2 years. It is
therefore possible that we missed some of the genetic effect
in the first 3 years. Furthermore, the methods of assessing
severity were different; we used Modified Larsen scores as a
quantitative measure of structural damage, rather than com-
parison of genotypes between erosive and nonerosive RA.
Variants of IL-4 and IL-13 have been associated extensively
with atopic asthma, serum concentrations of IgE and suscep-
tibility to Crohn's disease [4,5,13,19-21]. Because these
genes signal through a common pathway, gene-gene interac-
tions may modify the effect of single SNPs in the IL-4/IL-13
pathway. Interaction analysis between IL-4/IL-13 and their
shared receptor is of particular interest because gene-gene
interactions may modify the effects of individual SNPs in the IL-
4/IL-13 pathway, and evidence of epistasis has been reported
Table 2
The extend of LD across the IL-13 and IL-4 genes
SNP1 SNP2 SNP3 SNP4 SNP5
SNP1 0.5307 0.5333 0.3145 0.4065
SNP2 0.2953 0.1843 0.2393
SNP3 0.9728 0.9848
SNP4 0.9225
SNP5
D' values among all single nucleotide polymorphism (SNP) pairs are 
shown. SNP1 is rs1800925, SNP2 is rs1295686, SNP3 is 
rs2227284, SNP4 is rs2243263, and SNP5 is rs2243267. LD, 
linkage disequilibrium.
Table 3
Haplotype frequencies and RA susceptibility
Haplotype IL-13 haplotypes IL-4 haplotypes
SNP1 SNP2 RA Controls OR (95% CI) P SNP3 SNP4 SNP5 RA Controls OR (95% CI) P
1 C G 0.754 0.747 1.00 - C G G 0.760 0.766 1.00 -
2 T A 0.110 0.107 1.02 (0.82–1.26) 0.86 A G C 0.136 0.128 0.89 (0.65 – 1.23) 0.49
3 C A 0.065 0.078 0.83 (0.63–1.09) 0.19 A C G 0.090 0.091 1.38 (1.00 – 1.91) 0.96
4 T G 0.068 0.067 1.02 (0.77–1.35) 0.91
The frequency of haplotypes in each control is shown. SNP1 is rs1800925, SNP2 is rs1295686, SNP3 is rs2227284, SNP4 is rs2243263, and SNP5 is rs2243267. 
CI, confidence interval; OR, odd ratio; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism.Available online http://arthritis-research.com/content/10/4/R80
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in a asthma and type 1 diabetes [4,22,23]. Because the IL-4
and IL-13 genes are located on the same chromosome, we
only investigated potential pair-wise interactions between
each gene and IL-4R. Only suggestive evidence for epistasis
was detected between IL-4R Q551R and IL-13 -1112, but
this was not statistically significant after correction.
Conclusion
We conclude that polymorphism in IL-4/IL-13/IL-4Ra loci do
not contribute significantly in the genetic background of RA
either individually or in combination.
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Table 4
Genotype frequencies of the genes involved in the IL-4/IL-13 
pathway and modified Larsen score
Gene SNP Genotypes Patients (n) Median LSa P
IL-13 rs1800925 TT 26 31.0
CT 271 27.0 0.8
CC 608 28.0
rs1295686 TT 26 33.5
CT 251 25.0 0.8
CC 580 28.0
IL-4 rs2227284 AA 56 27.0
AC 316 29.0 0.6b
CC 541 29.0
rs2243263 CC 8 41.5
AC 146 26.0 0.3
AA 738 28.0
rs2243267 CC 18 23.5
CG 218 29.0 0.9
GG 672 28.0
IL-4R rs1805010 GG 198 24.5
AG 460 30.0 0.5
AA 250 29.0
rs1801275 AA 38 28.0
AG 316 27.5 0.5
GG 558 29.0
aMaximum possible modified (Larsen score) is 160. bBy Cuzick's test 
for trend. SNP, single nucleotide polymorphism.Arthritis Research & Therapy    Vol 10 No 4    Marinou et al.
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